XML 56 R43.htm IDEA: XBRL DOCUMENT v3.3.1.900
Fair Value Measurement (Details 2)
$ in Thousands
12 Months Ended
Dec. 31, 2015
USD ($)
Assets:  
Fair value of level 3 financial instruments as of December 31, 2014 $ 322
Assumed payments made by Pfizer or assignee (390)
Fair value adjustments to co-promote termination liability 68
Note receivable Viking 4,782
Fair value of level 3 financial instrument assets as of December 31, 2015 4,782
Liabilities  
Fair value of level 3 financial instruments as of December 31, 2014 11,819
Assumed payments made by Pfizer or assignee (390)
Payments to CVR holders and other contingency payments (5,848)
Fair value adjustments to contingent liabilities 3,841
Fair value adjustments to co-promote termination liability 68
Fair value of level 3 financial instruments as of December 31, 2015 9,490
2019 Convertible Senior Notes | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Fair value of convertible debt 377,900
Viking Therapeutics, Inc.  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Equity Method Investment, Quoted Market Value $ 16,300